Clinical trials: Non-small-cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer
Lung cancer is the most common cancer worldwide, non-small cell lung cancer (NSCLC) comprises about 85% of all lung cancer cases, which is the leading cause of cancer mortality, and adenocarcinoma is the most prevalent subtype.
- Trial name
- NCT01871480
- Testing
- Group A:cytokine-induced killer cell +gefitinib, Group B:Gefitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Kunming Medical University
Non-Small-Cell Lung
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
- Trial name
- MAP (NCT07316062)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Lung Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue near the tumor.
- Trial name
- NCT00551369
- Testing
- SBRT
- Where
- 19 sites in United States
- Volunteers
- 33 people
- Sponsor
- Radiation Therapy Oncology Group
Psychosocial
Effects of Cancer Symptoms on Caregivers
The primary objectives are to: 1.1 identify and compare the experiences of minority and nonminority caregivers, including the prevalence and severity of physical (fatigue, sleep disturbance) and psychologic (depression, anxiety…
- Trial name
- NCT00351988
- Testing
- Phenomenological Interviews, Quantitative Interviews
- Where
- 4 sites in United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung
Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib
The majority of patients with advanced NSCLC treated with standard platinum based chemotherapy regimens ultimately develop disease progression. Active therapies with improved toxicity profiles are clearly needed in this setting.
- Trial name
- PECASO (NCT00473486)
- Testing
- pemetrexed, carboplatin, sorafenib
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- University Hospital Muenster
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
This is a Phase 1/2a open-label multicenter study to evaluate the safety, efficacy, and pharmacokinetics of CKD-703 in Advanced c-Met Expressing Solid Tumors, and in MET-Amplified and c-Met Overexpressing Non-Small Cell Lung…
- Trial name
- NCT07439094
- Testing
- CKD-703
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Neoplasms
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02222922
- Testing
- PF-06647020 Q3W, fluconazole, PF-06647020 Q2W
- Where
- 17 sites in United States, Spain
- Volunteers
- 138 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
The primary purpose of this study is to compare the efficacy of the study drug LY2875358, given together with erlotinib, against erlotinib, alone.
- Trial name
- Balise (NCT01897480)
- Testing
- LY2875358, Erlotinib
- Where
- 45 sites in Denmark, France and 7 more
- Volunteers
- 168 people
- Sponsor
- Eli Lilly and Company
Non-Small-Cell Lung Cancer
Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer
Determine tumor response rate and time to disease progression, survival and safety in total populations.
- Trial name
- NCT00063388
- Testing
- Cetuximab
- Where
- 8 sites in United States
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
NSCLC Stage IV
Alectinib-induced Endocrine Toxicity
The experimental Cohort A (male ALK+ ANSCLC patients receiving alectinib), the control Cohort B (female ALK+ ANSCLC patients receiving alectinib) and control Cohort C (male NON-ALK ANSCLC patients) were prospectively evaluated…
- Trial name
- TOSS-ALK (NCT06339554)
- Testing
- Alectinib 150 MG [Alecensa]
- Where
- Italy
- Volunteers
- 98 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Carcinoma, Non-Small-Cell Lung
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
This study is to determine if Stage III NSCLC patients treated with ipilimumab with thoracic radiation therapy followed by nivolumab monotherapy every 4 weeks for up to 12 months show an improved 12-month Progression Free…
- Trial name
- NCT03663166
- Testing
- Thoracic Radiotherapy, Platinum Based Chemotherapy, ipilimumab
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non Small Cell Lung Cancer
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.
- Trial name
- CREATE (NCT05059951)
- Testing
- Immune checkpoint inhibitor
- Where
- China
- Volunteers
- 15,000 people
- Sponsor
- Hunan Province Tumor Hospital
Solid Tumor
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Genes contain genetic code which tell the body which proteins to make. Some types of cancer are caused by changes, or mutations, in a gene called KRAS.
- Trial name
- NCT06364696
- Testing
- ASP4396
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Cancer, Non Small Cell Lung Cancer
Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
The primary purpose of this study is to explore the safety and tolerability of AZD0530 in combination with carboplatin and paclitaxel in Japanese patients with non small cell lung cancer and epithelial ovarian cancer.
- Conditions
- Cancer, Non Small Cell Lung Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT01000896
- Testing
- AZD0530, Carboplatin, paclitaxel
- Where
- 2 sites in Japan
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Maligant Solid Tumor, Head & Neck Cancer
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
This study is a prospective, single-arm, open-label, dose-escalation study. A total of 4 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles.
- Conditions
- Maligant Solid Tumor, Head & Neck Cancer, Thyroid Cancer, Lung Cancer - Non Small Cell Squamous
- Trial name
- NCT07459283
- Testing
- INN805
- Where
- China
- Volunteers
- 10 people
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.
Non-small-cell Lung Cancer
Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients
Cancer is one of the leading health issues in this country and worldwide. Angiogenesis is an essential process for tumoral growth and metastasis.
- Trial name
- NCT01136083
- Testing
- Exercise training, Usual care
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Carcinoma, Non-Small-Cell Lung
A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy
Open label Enrollment in the order of confirmation of eligibility and HPV+ tumor status Prospective stratification based on 3 factors, epidermal growth factor receptor (EGFR) mutation status, performance status and first-line…
- Trial name
- NCT02531854
- Testing
- ADXS11-001, Pemetrexed
- Sponsor
- Advaxis, Inc.
Leptomeningeal Metastasis, Leptomeningeal Disease
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
The FORESEE Study is a multi-center, prospective clinical trial enrolling patients with Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM).
- Conditions
- Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer
- Trial name
- FORESEE (NCT05414123)
- Testing
- CNSide
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Biocept, Inc.
Non-small-cell Lung Cancer
Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer
This Phase II randomized study is to determine the efficacy and toxicity of Nimotuzumab in combined with chemoradiotherapy for unresectable,local advanced squamous cell lung cancer.
- Trial name
- NCT02577341
- Testing
- Nimotuzumab, docetaxel and cisplatin, daily RT to the chest
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.